儿童肾移植术后供者特异性抗体的产生及其影响

陈刚

doi:10.3969/j.issn.1674-7445.2022.03.004

儿童肾移植术后供者特异性抗体的产生及其影响

doi: 10.3969/j.issn.1674-7445.2022.03.004

陈刚^,

430030 武汉，华中科技大学同济医学院附属同济医院器官移植研究所器官移植教育部重点实验室国家卫生健康委员会器官移植重点实验室中国医学科学院器官移植重点实验室

基金项目:

湖北省技术创新重大项目 2017ACA096

同济医院临床研究领航项目 2019CR108

详细信息

作者简介:

通讯作者:
陈刚, Email: gchentj@163.com

中图分类号: R617, R726
计量
- 文章访问数: 397
- HTML全文浏览量: 189
- PDF下载量: 108
- 被引次数: 0
出版历程
- 收稿日期: 2022-02-05
- 网络出版日期: 2022-04-29
- 刊出日期: 2022-05-15

Production and influence of donor specific antibodies after pediatric kidney transplantation

Chen Gang^,

Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Key Laboratory of Organ Transplantation of Ministry of Education, Key Laboratory of Organ Transplantation of National Health Commission of China, Key Laboratory of Organ Transplantation of Chinese Academy of Medical Sciences, Wuhan 430030, China

More Information

Corresponding author: Chen Gang, Email: gchentj@163.com

摘要

摘要: 近年来，我国儿童肾移植发展迅速，但仍缺乏足够的有关移植肾长期存活方面的临床数据。成人肾移植术后新生供者特异性抗体（dnDSA）的产生及其介导的慢性排斥反应是影响移植肾长期存活的重要危险因素，但儿童的免疫系统发育尚未完全，其术后dnDSA的产生及其对移植肾和受者的影响可能与成人有所不同。因此，本文就儿童免疫系统的特点、儿童肾移植术后供者特异性抗体（DSA）的产生及影响、儿童肾移植术后DSA产生的危险因素进行总结，并对预防策略提出建议，旨在为提高儿童肾移植术后移植肾的长期存活提供参考，促进我国儿童肾移植的发展。
- 肾移植 /
- 儿童 /
- 免疫系统 /
- 供者特异性抗体 /
- 抗体介导的排斥反应 /
- 人类白细胞抗原 /
- 移植肾失功
Abstract: In recent years, pediatric kidney transplantation has developed rapidly in China. However, clinical data related to the long-term survival of renal allografts are still lacking. The production of de novo donor specific antibody (dnDSA)and its mediated chronic rejection after adult kidney transplantation are pivotal risk factors affecting the long-term survival of renal allografts. Nevertheless, immune system in children has not fully developed. Hence, the production of dnDSA after kidney transplantation and its influence upon renal allografts and recipients might differ from those of adult. In this article, the characteristics of pediatric immune system, the production and influence of donor specific antibody (DSA) after pediatric kidney transplantation and the risk factors of the production of DSA after pediatric kidney transplantation were reviewed and certain suggestions were proposed for prevention strategies, aiming to provide reference for prolonging the long-term survival of renal allografts after pediatric kidney transplantation and promote the development of pediatric kidney transplantation in China.
- Kidney transplantation /
- Child /
- Immune system /
- Donor specific antibody /
- Antibody-mediated rejection /
- Human leukocyte antigen /
- Renal allograft dysfunction

HTML全文

下载: 全尺寸图片幻灯片

参考文献(30)

[1]	WALDECKER CB, ZGOURA P, SEIBERT FS, et al. Biopsy findings after detection of de novo donor-specific antibodies in renal transplant recipients: a single center experience[J]. J Nephrol, 2021, 34(6): 2017-2026. DOI: 10.1007/s40620-021-01040-y.
[2]	LIU W, ZHAO J, KANG ZY, et al. De novo donor-specific HLA antibodies reduce graft survival rates and increase the risk of kidney transplant rejection: a single-center retrospective study[J]. Transpl Immunol, 2021, 68: 101430. DOI: 10.1016/j.trim.2021.101430.
[3]	DHARNIDHARKA VR, FIORINA P, HARMON WE. Kidney transplantation in children[J]. N Engl J Med, 2014, 371(6): 549-558. DOI: 10.1056/NEJMra1314376.
[4]	EVERLY MJ, BRILEY KP, HAISCH CE, et al. Racial differences in incident de novo donor-specific anti-HLA antibody among primary renal allograft recipients: results from a single center cohort study[J]. Transpl Int, 2017, 30(6): 566-578. DOI: 10.1111/tri.12937.
[5]	EVERLY MJ, REBELLATO LM, HAISCH CE, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts[J]. Transplantation, 2013, 95(3): 410-417. DOI: 10.1097/TP.0b013e31827d62e3.
[6]	DEMIROK A, RANZIJN C, LARDY J, et al. Evaluation of the current post-transplantation human leukocyte antigen antibody screening in pediatric renal transplant recipients[J]. Pediatr Transplant, 2019, 23(2): e13338. DOI: 10.1111/petr.13338.
[7]	SHARMA A, TAVERNITI A, GRAF N, et al. The association between human leukocyte antigen eplet mismatches, de novo donor-specific antibodies, and the risk of acute rejection in pediatric kidney transplant recipients[J]. Pediatr Nephrol, 2020, 35(6): 1061-1068. DOI: 10.1007/s00467-020-04474-x.
[8]	CIONI M, NOCERA A, INNOCENTE A, et al. De novo donor-specific HLA antibodies developing early or late after transplant are associated with the same risk of graft damage and loss in nonsensitized kidney recipients[J]. J Immunol Res, 2017: 1747030. DOI: 10.1155/2017/1747030.
[9]	GINEVRI F, NOCERA A, COMOLI P, et al. Posttransplant de novo donor-specific HLA antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection[J]. Am J Transplant, 2012, 12(12): 3355-3362. DOI: 10.1111/j.1600-6143.2012.04251.x.
[10]	CHARNAYA O, TUCHMAN S, MOUDGIL A. Results of early treatment for de novo donor-specific antibodies in pediatric kidney transplant recipients in a cross-sectional and longitudinal cohort[J]. Pediatr Transplant, 2018, 22(2): e13108. DOI: 10.1111/petr.13108.
[11]	FERNANDEZ HE. Application and interpretation of histocompatibility data in pediatric kidney transplantation[J]. Curr Opin Organ Transplant, 2017, 22(4): 426-432. DOI: 10.1097/MOT.0000000000000425.
[12]	FILIPPONE EJ, FARBER JL. The problem of subclinical antibody-mediated rejection in kidney transplantation[J]. Transplantation, 2021, 105(6): 1176-1187. DOI: 10.1097/TP.0000000000003543.
[13]	VELIDEDEOGLU E, CAVAILLÉ-COLL MW, BALA S, et al. Summary of 2017 FDA Public Workshop: antibody-mediated rejection in kidney transplantation[J]. Transplantation, 2018, 102(6): e257-e264. DOI: 10.1097/TP.0000000000002141.
[14]	VO AA, AUBERT O, HAAS M, et al. Clinical relevance of posttransplant DSAs in patients receiving desensitization for HLA-incompatible kidney transplantation[J]. Transplantation, 2019, 103(12): 2666-2674. DOI: 10.1097/TP.0000000000002691.
[15]	KONVALINKA A, TINCKAM K. Utility of HLA antibody testing in kidney transplantation[J]. J Am Soc Nephrol, 2015, 26(7): 1489-1502. DOI: 10.1681/ASN.2014080837.
[16]	TAFULO S, MALHEIRO J, SANTOS S, et al. HLA class Ⅱ eplet mismatch load improves prediction of dnDSA development after living donor kidney transplantation[J]. Int J Immunogenet, 2021, 48(1): 1-7. DOI: 10.1111/iji.12519.
[17]	AHLENSTIEL-GRUNOW T, PAPE L. Diagnostics, treatment, and immune response in BK polyomavirus infection after pediatric kidney transplantation[J]. Pediatr Nephrol, 2020, 35(3): 375-382. DOI: 10.1007/s00467-018-4164-3.
[18]	TANNÉ C, ROY P, FROBERT É, et al. Cytomegalovirus infection in the first year after pediatric kidney transplantation[J]. Nephrol Ther, 2019, 15(1): 44-50. DOI: 10.1016/j.nephro.2018.04.003.
[19]	TSAMPALIEROS A, KNOLL GA, MOLNAR AO, et al. Corticosteroid use and growth after pediatric solid organ transplantation: a systematic review and Meta-analysis[J]. Transplantation, 2017, 101(4): 694-703. DOI: 10.1097/TP.0000000000001320.
[20]	STROMMEN AM, MOSS MC, GOEBEL J, et al. Donor-specific antibodies in a pediatric kidney transplant population-prevalence and association with antiproliferative drug dosing[J]. Pediatr Transplant, 2019, 23(6): e13511. DOI: 10.1111/petr.13511.
[21]	HOEGY D, BLEYZAC N, ROBINSON P, et al. Medication adherence in pediatric transplantation and assessment methods: a systematic review[J]. Patient Prefer Adherence, 2019, 13: 705-719. DOI: 10.2147/PPA.S200209.
[22]	GAJARDO M, DELUCCHI A, PÉREZ D, et al. Long-term outcome of early steroid withdrawal in pediatric renal transplantation[J]. Pediatr Transplant, 2021, 25(8): e14096. DOI: 10.1111/petr.14096.
[23]	SHEN Q, FANG X, MAN X, et al. Pediatric kidney transplantation in China: an analysis from the IPNA Global Kidney Replacement Therapy Registry[J]. Pediatr Nephrol, 2021, 36(3): 685-692. DOI: 10.1007/s00467-020-04745-7.
[24]	LIU L, ZHANG H, FU Q, et al. Current status of pediatric kidney transplantation in China: data analysis of Chinese Scientific Registry of Kidney Transplantation[J]. Chin Med J (Engl), 2014, 127(3): 506-510.
[25]	陈刚. 中国儿童肾移植的现状及对未来发展的思考[J]. 中华器官移植杂志, 2020, 41(1): 1-2. DOI: 10.3760/cma.j.issn.0254-1785.2020.01.001. CHEN G. Current situation of renal transplantation in children in China and its future development[J]. Chin J Organ Transplant, 2020, 41(1): 1-2. DOI: 10.3760/cma.j.issn.0254-1785.2020.01.001.
[26]	CHARNAYA O, JONES J, PHILOGENE MC, et al. Eplet mismatches associated with de novo donor-specific HLA antibody in pediatric kidney transplant recipients[J]. Pediatr Nephrol, 2020, 36(12): 3971-3979. DOI: 10.1007/s00467-021-05078-9.
[27]	SYPEK MP, HIHO S, CANTWELL L, et al. Human leukocyte antigen eplet mismatches and long-term clinical outcomes in pediatric renal transplantation: a pragmatic, registry-based study[J]. Pediatr Transplant, 2020, 24(4): e13705. DOI: 10.1111/petr.13705.
[28]	KAUSMAN JY, WALKER AM, CANTWELL LS, et al. Application of an epitope-based allocation system in pediatric kidney transplantation[J]. Pediatr Transplant, 2016, 20(7): 931-938. DOI: 10.1111/petr.12815.
[29]	LARKINS NG, WONG G, TAVERNITI A, et al. Epitope matching in kidney transplantation: recent advances and current limitations[J]. Curr Opin Organ Transplant, 2019, 24(4): 370-377. DOI: 10.1097/MOT.0000000000000657.
[30]	CHANDAR J, CHEN L, DEFREITAS M, et al. Donor considerations in pediatric kidney transplantation[J]. Pediatr Nephrol, 2021, 36(2): 245-257. DOI: 10.1007/s00467-019-04362-z.